Introduction
Lung cancer is one of the commonest cancers and cause of cancer related mortality worldwide. It accounts for 12.7% of all new cancer cases and 18.2% of all cancer related deaths, throughout the world (Parkin DM) . In India, it is the commonest and most lethal cancer among males accounting for 10.9% of all cancer cases and 13% of cancer related mortality (Parkin DM) . Despite recent advances in biological understanding and newer treatment modalities, the overall outcome of lung cancer remains poor. Survival is better in patients who receive optimum anticancer treatment compared with those who do not (Fry et al., 1999) . In a disease with increasing incidence and poor survival, outcome can only be improved with the delivery of adequate anticancer treatment and early diagnosis.
There are variations in delivery and utilization of treatment in lung cancer worldwide. In actual practice, a large number of patients of lung cancer do not receive , Vinod Raina 1 any anticancer treatment. These figures vary from 19% in USA, 33% in Australia, 37% in Scotland, and 50% in Ireland and New Zealand (Mahmud et al., 2003; Stevens et al., 2007; Erridge et al., 2008; Vinod et al., 2008) . Even among patients receiving anticancer treatment, there is gross underutilization of curative treatment modalities.
Studies from United States demonstrate that 30-60% of cases of early stage lung cancer don't undergo surgery (Esnaola et al., 2008; Cykert et al., 2010a) . Similarly only 36-70% patients receive radiotherapy in contrast to guideline recommendation of radiotherapy use requirement in up to 76% of lung cancer patients (Delaney et al., 2005) .
There are many valid reasons because of which optimum treatment can't be administered in lung cancer. Most patients present with advanced disease that is often incurable. This leads clinicians to therapeutic nihilism. Old age, co morbidities, poor performance status and social reasons are other factors which limit the ability to treat patients optimally. There is paucity of data regarding treatment utilization rates and patterns in NSCLC from India.
In context of lung cancer, particularly non small cell lung cancer (NSCLC), radical treatment consists of surgery and radical doses of radiotherapy with or without chemotherapy (Ustaalioglu et al., 2013) . Majority of the patients present with advanced stage disease which is not amenable to curative treatment modalities. We analyzed records of our patients with NSCLC who were registered at our centre in last 3 years, which is a regional cancer centre registering approximately 8000 new cancer cases every year.
Materials and Methods
We screened case records of 370 consecutive, pathologically confirmed non small cell lung cancer patients, registered at our centre in Lung Cancer Chemotherapy Clinic between July 2008 and June 2011 (a period of 3 years). This clinic is primarily run by medical oncology team in close collaboration with pulmonologists, surgical oncologists and radiation oncologists. Approximately 3-5 new cases of lung cancer are registered at this clinic every week. The cases are referred from various general and speciality hospitals of northern India. Clinical, demographic, treatment and outcome related informations were collected from case record files and entered in a predesigned proforma. Disease was restaged according to AJCC staging system 7th edition based on the available clinical and radiological findings. Patients were treated as per departmental treatment protocols according to disease stage, performance status, co morbidities and patient's preference. Permission for viewing case records was obtained from the institute's committee and the medical record department. Confidentiality of the patient's identity was maintained.
Patients were considered on continuous follow up if the last visit was within 3 months of data censoring. In cases where last visit was more than 3 months ago, attempts were made to contact the patients by telephone and/or a reply letter. Patients were followed from the date of registration to the date of death and were censored at the date they were last known to be alive i.e. date of last follow up (if lost to follow-up) or May 31, 2012, whichever came first.
Statistical analysis
The data was censored on 31 st May 2012 or last follow up date (if lost to follow up). Descriptive statistics was used for describing demographic and clinical characteristics. For comparison of two groups (patients receiving or not receiving radical treatment) Chi square and Fischer Exact test were used. Logistic regression was used to estimate odds ratio. The Survival was estimated by the Kaplan-Meier method. Overall survival was defined as duration from registration till death due to any cause and progression free survival was defined as duration from registration till occurrence of disease progression or death. Analysis was done using the Stata software (Release 9.0, Stata Corp.).
Results
A total of 370 pathologically confirmed cases of NSCLC were identified. Only 261 (70.54%) patients received some form of anticancer treatment. Out of these 261 patients, 68 (26.05%) were stage 1-3A who were potentially resectable and 104 (39.8%) were of stage 1-3B who were amenable to radical treatment modalities. Remaining 157 patients were of stage 4 disease and excluded from further analysis. Only 33 out of these 104 (31.7%) patients received curative intent treatment, i.e. surgery or radical radiotherapy. Out of these 33 patients, 14 underwent surgery and 19 received radical doses of radiotherapy as curative treatment modality. The median age of this cohort was 58 years (range 36-78 years) with male: female ratio of 10:1. Squamous cell carcinoma was the most common histological subtype among these patients. Radical radiotherapy was delivered either upfront as primary treatment modality (1 patient) or in a sequential manner (18 patients) after 4-6 cycles of chemotherapy. Most of the patients received radiotherapy doses between 45-60 Gy through conventional fractionation. Two patients underwent stereotactic body radiation (SBRT) and received a dose of 40 Gy in 10 fractions. Most common chemotherapy regimen used was the combination of Paclitaxel and Carboplatin (93.3%). Among 14 patients, who underwent surgery, 5 patients received neo adjuvant chemotherapy, 4 patients received adjuvant chemotherapy and 6 patients received post op radiotherapy.
Comparison of the baseline characteristics of the patients receiving or not receiving radical treatment despite having stage 1-3 B disease is shown in Table 1 . There was no statistically significant difference between the two groups for all factors. Stage differences were of borderline significance (p=0.054). 
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Details of treatment received are shown in Table 2 . Out of 71 patients who didn't receive radical treatment, 20 (28.17%) didn't receive any chemotherapy. They were treated either with TKI (tyrosine kinase inhibitors) with or without palliative radiotherapy or palliative radiotherapy alone. In this group of patients who didn't receive radical treatment, 51 (71.8%) received chemotherapy but 29 (56.8%) of these patients either had progressive disease or not evaluated for response (lost to follow up). On the other hand, in radical treatment arm, 27 out of 33 (81.8%) received chemotherapy and none of them had disease progression after chemotherapy.
After a median follow up time of 18.4 months, the median PFS was 14.47 months for the patients who received radical treatment and 5.36 months for the patients who did not received (p<0.001). Median OS for the patients who didn't received radical treatment was 12.3 months while for patients who have received radical treatment, median hasn't reached (p<0.001).
Discussion
Majority of the patients of NSCLC usually present in advanced stage and generally are not suitable for curative treatment. The management of NSCLC involves multidisciplinary approach and optimal use of the available treatment modalities. Guidelines recommend surgery or radical doses of radiotherapy along with chemotherapy for stage 1-3A, radical radiotherapy with chemotherapy for stage 3B and palliative chemotherapy with or without palliative radiotherapy or TKIs for stage 4 disease (Crino et al., 2010; Peters et al., 2012a; 2012b) . In actual practice, not all patients receive the optimum treatment (Vinod et al., 2010) . The reasons may be poor PS, advance age, co morbidities, social factors and patient's preference.
We demonstrated in this study that in our practice 29.46% patients of NSCLC didn't receive any anticancer treatment and out the patients who were amenable to radical treatment approach, only 31.7% could receive the curative intent treatment. Treatment utilization rates in lung cancer varies worldwide and so the optimal treatment rates. In our cohort only 15% of potentially resectable patients could undergo surgery. These figures vary from 40-70% in studies from United States. Racial differences in proportion of patients undergoing surgery, apart from disease related factors and co morbidities have been observed in these studies (Esnaola et al., 2008; Cykert et al., 2010b) . It is estimated that 61-76% patients would require radiotherapy at some point of time, if used optimally in lung cancer but in actual practice up to 40% receive it (Tyldesley et al., 2001; Delaney et al., 2003) . In our group of patients only 18.26% (19/104) patients could receive radical doses of radiotherapy.
Underutilization of treatment strategies results in poor survival in lung cancer (Fry et al., 1999) . This is evident from our analysis also which demonstrate a clear difference in survival of patients treated adequately with curative intent versus remaining patients. Major reasons for inferior survival observed in this population were progressive disease or lost to follow up while being on chemotherapy and many patients (28.17%) were treated with palliative intent only with palliative radiotherapy or TKI. In our analysis we found that patients who didn't receive chemotherapy or had progressive disease or lost to follow up had more likelihood of not receiving radical treatment. Patients who have progressive disease on one treatment modality are anyway more likely to have inferior outcome but on the other hand if the curative modalities are instituted early in the course of the disease, some of these patients could be salvaged. We didn't found any difference in terms of age, performance status, stage, histology, haemoglobin or serum albumin. This may be due to selection and referral bias in hospital based data which is reflected by the fact that majority of the patients of this cohort had a good performance status.
This is a single centre data from India, which reflects inadequacy of treatment utilization in patients with NSCLC. A bigger population based data including all patients whether treated or not, could show the actual scenario of treatment utilization rates and pattern in this country. Another limitation of this study was its In conclusion, in actual practice, there is gross underutilization of curative treatment options in the management of NSCLC. The use of radical treatment modalities is associated with significantly better outcome. Every attempt should be made for optimum utilization of all the treatment modalities in the management of NSCLC.
